28 February 2019 
EMA/CHMP/41336/2019 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Dupixent 
dupilumab 
On 28 February 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Dupixent. The marketing authorisation holder for this medicinal product is sanofi-aventis groupe. 
The CHMP adopted a new indication as follows: 
“Asthma 
Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment 
for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised 
FeNO (see section 5.1), who are inadequately controlled with high dose ICS plus another medicinal 
product for maintenance treatment.” 
For information, the full indications for Dupixent will be as follows:2 
“Atopic Dermatitis 
Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients 
who are candidates for systemic therapy. 
Asthma 
Dupixent is indicated in adults and adolescents 12 years and older as add-on 
maintenance treatment for severe asthma with type 2 inflammation characterised by 
raised blood eosinophils and/or raised FeNO (see section 5.1), who are inadequately 
controlled with high dose ICS plus another medicinal product for maintenance 
treatment.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
authorisation has been granted by the European Commission. 
Dupixent  
EMA/CHMP/41336/2019 
Page 2/2 
 
  
  
